Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
The in vivoanticancer efficacy of nanoparticle-mediated drug delivery depends on the association between the drug and its carrier. Here, the authors use FRET to show that the drug hydrophobicity, and miscibility with the carrier, influence nanoparticle accumulation in murine tumour models.
Enregistré dans:
Auteurs principaux: | Yiming Zhao, François Fay, Sjoerd Hak, Jose Manuel Perez-Aguilar, Brenda L. Sanchez-Gaytan, Brandon Goode, Raphaël Duivenvoorden, Catharina de Lange Davies, Astrid Bjørkøy, Harel Weinstein, Zahi A. Fayad, Carlos Pérez-Medina, Willem J. M. Mulder |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d90fceee65ae4c4ca9f5fa1e73acfa06 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
par: Carlos Pérez-Medina, et autres
Publié: (2016) -
Ormeloxifene nanotherapy for cervical cancer treatment
par: Chauhan N, et autres
Publié: (2019) -
Molecular targets in arthritis and recent trends in nanotherapy
par: Roy K, et autres
Publié: (2015) -
Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers
par: Yang Liu, et autres
Publié: (2017) -
Reduced graphene oxide–silver nanoparticle nanocomposite: a potential anticancer nanotherapy
par: Gurunathan S, et autres
Publié: (2015)